Pulmonary Tumor Thrombotic Microangiopathy

Report of 3 Cases and Review of the Literature

Eukene Gainza, MD, Sara Fernández, MD, Daniel Martínez, MD, Pedro Castro, MD, PhD,
Xavier Bosch, MD, PhD, José Ramírez, MD, PhD, Arturo Pereira, MD, PhD,
María T. Cibeira, MD, PhD, Jordi Esteve, MD, PhD, and Josep M. Nicolás, MD, PhD

INTRODUCTION

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare clinical entity where tumor cell embolisms in pulmonary circulation induce thrombotic microangiopathy (TMA), respiratory failure, and subacute cor pulmonale. We describe 3 cases of PTTM that presented as the initial manifestation of metastatic gastric adenocarcinoma with TMA and pulmonary infiltrates.

CASE REPORTS

We describe 3 cases of PTTM that presented as the initial manifestation of metastatic gastric adenocarcinoma with TMA and pulmonary infiltrates. All 3 patients had similar clinical and laboratory features, which included moderate thrombocytopenia without renal failure, hemolysis with extremely high serum lactate dehydrogenase levels, leukoerythroblastosis in peripheral blood smear, altered coagulation tests, lymphadenopathy, and interstitial pulmonary infiltrates. All patients died within 2 weeks of diagnosis. Two cases were initially misdiagnosed as idiopathic thrombotic thrombocytopenic purpura and treated with plasma exchange with no response. One patient had bone marrow infiltration by malignant cells. Autopsies revealed PTTM associated with gastric disseminated adenocarcinoma (signet-ring cell type in 2 patients and poorly differentiated type in 1).

PTTM should be considered in the differential diagnosis of patients with fulminant microangiopathic hemolytic anemia, such as atypical thrombocytopenic thrombocytopenic purpura, mainly those with pulmonary infiltrates, disseminated intravascular coagulation, or Trousseau syndrome.

From the Hematology Department (EG, MTC, JE); Medical Intensive Care Unit (SF, PC, JMN); Pathology Department (DM, JR); Internal Medicine Department (XB); and Hemotherapy-Hemostasis Department (AP), Hospital Clinic, Barcelona, Spain.

Correspondence: Pedro Castro Rebollo, MD, PhD, Medical Intensive Care Unit, Hospital Clinic, Villarroel 170, 08036. Barcelona, Spain (e-mail: pcastro@clinic.ub.es).

Financial support and conflicts of interest: The authors have no funding or conflicts of interest to disclose.

Copyright © 2014 by Lippincott Williams & Wilkins.

ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000219
Case 2

A 34-year-old Peruvian man without relevant past medical history presented to the emergency room referring 1 month of asthenia, cough, headache and lumbar pain. Physical examination showed pale skin, jaundice, laterocervical lymphadenopathies and bilateral basal rales. In the laboratories he presented elevated liver enzymes (aspartate aminotransferase 388 U/L, alanine aminotransferase 75 U/L, alkaline phosphatase 450 U/L), signs of MAHA (hemoglobin 81 g/L, total bilirubin 4.2 mg/dL, direct bilirubin 1.3 mg/dL, reticulocyte count 265 × 10⁹/L, LDH 2286 U/L, haptoglobin 0.071 g/L, and peripher blood smear with schistocytes) and platelet count of 94 × 10⁹/L. Coagulation test showed PT 15 sec, aPTT 30 sec, fibrinogen 1.8 g/L and increased FDPs. Creatinine was normal. DAT was negative. Chest X-ray and CT scan demonstrated bilateral interstitial infiltrates, infracentrimetric mediastinal and retroperitoneal lymphadenopathies, hypodense hepatic lesions and ascites. Bone marrow aspirate excluded infiltration by malignant cells. Corticosteroids and plasma exchange were administered with no improvement. A lymph node and a percutaneous liver biopsy with a Tru-Cut needle were performed showing metastatic gastric adenocarcinoma of signet-ring cell type in the lymph node and sinusoidal infiltration by carcinoma cells in the liver. The outcome was complicated with hemoperitoneum after liver biopsy and the patient was transferred to the ICU. Administration of chemotherapy was ruled out due to poor patient’s clinical condition. Twelve days after admission the patient died due to refractory hypoxemia. Autopsy was performed.

Case 3

A 24-year-old Bolivian woman without relevant past medical history was referred to our hospital for further study of 3-weeks back pain, nausea and vomiting. At admission she appeared pale. Laboratory tests showed increased alkaline phosphatase (855 U/L), signs of MAHA (hemoglobin 93 g/dL, total bilirubin 8.1 mg/dL, direct bilirubin 2.3 mg/dL, reticulocyte count 267 × 10⁹/L, LDH 8450 U/L, haptoglobin 0.04 g/L, and schistocytes in peripheral blood smear), 94 × 10⁹/L platelets and signs of disseminated intravascular coagulopathy (DIC) (hemoglobin 66 g/L, total bilirubin 4.1 mg/dL, direct bilirubin 0.8 mg/dL, reticulocyte count 190 × 10⁹/L, lactate dehydrogenase (LDH) 3057 U/L, undetectable haptoglobin, and schistocytes in the peripheral blood smear). White blood cell count and creatinine were normal. Platelet count was 100 × 10⁹/L, prothrombin time (PT) was 14 sec, activated partial thromboplastin time (aPTT) was 26 sec, fibrinogen was 2.3 g/L and fibrinogen degradation products (FDPs) were increased. The direct antiglobulin (Coombs) test (DAT) was negative. Bone marrow aspiration detected erythrophagocytosis without abnormalities in other lineages. Chest X-ray demonstrated bilateral interstitial pulmonary infiltrates (Figure 1A) and the patient was hypoxicemic. He was admitted to the ICU with an initial diagnosis of TTP and plasma exchange therapy was started due to poor patient’s clinical condition. Twelve days after admission the patient died due to multiorgan dysfunction due to several complications, such as pulmonary distress and Staphylococcus aureus pneumonia. Autopsy was not done.

### Table 1. Main Clinical and Laboratory Features of the 3 Cases

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>36</td>
<td>34</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>Presenting symptoms</td>
<td>Weakness, dark urine</td>
<td>Cough, back pain</td>
</tr>
<tr>
<td>Laboratory test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td>66</td>
<td>95</td>
</tr>
<tr>
<td>Platelet count (×10⁹/L)</td>
<td>100 × 10⁹</td>
<td>81 × 10⁹</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>3057</td>
<td>2286</td>
</tr>
<tr>
<td>PT (sec)</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>aPTT (sec)</td>
<td>26</td>
<td>30</td>
</tr>
<tr>
<td>Fibrinogen (g/L)</td>
<td>2.3</td>
<td>1.8</td>
</tr>
<tr>
<td>FDPs</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Peripheral blood smear</td>
<td>Schistocytes</td>
<td>Schistocytes</td>
</tr>
<tr>
<td>Leukoerythroblasticosis</td>
<td>35%</td>
<td>35%</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>Erythroid hyperplasia</td>
<td>Erythroid hyperplasia</td>
</tr>
<tr>
<td>Lymphadenopathies</td>
<td>Mediastinal</td>
<td>Laterocervical Mediastinal</td>
</tr>
<tr>
<td>Pulmonary infiltrates</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Plasma exchange</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Outcome</td>
<td>Death</td>
<td>Death</td>
</tr>
<tr>
<td>LOS (days)</td>
<td>2</td>
<td>12</td>
</tr>
</tbody>
</table>

Abbreviations: ADAMTS-13 = A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13; aPTT = activated partial thromboplastin time; FDPs = fibrin degradation products; LDH = lactate dehydrogenase; LOS = length of stay (from admission to death); PT = prothrombin time.
Leukoerythroblastosis was also present in the peripheral blood smear (Case 3). A CT scan demonstrated interstitial bilateral infiltrates, hepatic lesions suggestive of multiple metastasis and retroperitoneal lymphadenopathies. A gastrointestinal endoscopy was performed, observing an irregularly shaped ulcer whose biopsy was compatible with gastric adenocarcinoma. Bone marrow was infiltrated with neoplastic epithelial cells (Figure 1C). After 48 hours of admission the patient presented multiple organ dysfunction syndrome. As the prognosis was fatal, no life support measures were initiated and the patient died. An autopsy was performed.

Comment

In the 3 cases, anatomopathologic reports revealed gastric adenocarcinoma (2 signet-ring cell type, 1 poorly differentiated type [Case 3]), widespread microscopic metastatic deposits, tumor cell embolism with local thrombosis in the pulmonary arteries and arterioles, and fibrocellular intimal proliferation (Figure 1D-E). Carcinomatous lymphangitis was also present in the autopsies performed (Figure 1F). These findings confirmed the diagnosis of PTTM secondary to microscopic tumor cell embolism due to disseminated gastric adenocarcinoma.

DISCUSSION

PTTM is a rare clinicopathologic entity named by Von Hervay in 1990, but first described by Brill and Robertson in 1937 with the term “subacute cor pulmonale”. Although detailed pathogenesis remains to be clarified, it seems that embolization of tumoral cells into the pulmonary vessels induce endothelial damage and create a procoagulant environment with local activation of coagulation and fibrocellular intimal proliferation, leading to thrombosis and stenosis of vessels, with resulting pulmonary hypertension and MAHA. Recent reports suggest that vascular endothelial growth factor, tissue factor, and activated alveolar macrophages in the lung via expression of platelet-derived growth factor, may contribute to the onset and/or progression of PTTM promoting fibrocellular intimal proliferation. In addition, systemic activation of coagulation involves the generation of intravascular fibrin and the consumption of procoagulants, leading to DIC.

Although PTTM has been observed in 0.9% to 3.3% of autopsy case studies with extrathoracic malignancies, only a few cases are diagnosed antemortem. Different neoplasms have been reported to be associated with PTTM, but adenocarcinomas are the most frequently related. Gastric carcinoma is the most common (up to 26% of the cases described in the literature) followed by breast (21%), prostate (13%), and lung (10%) carcinoma. Although less frequent, PTTM has also been observed in hematologic malignancies such as Hodgkin lymphoma, aggressive non-Hodgkin lymphoma (NHL) and myeloma. Furthermore, a high incidence of PTTM, up to 16.7%, has been described in the context of gastric carcinomas (3.3% in malignant tumors in general). It is not well known why gastric carcinoma is more frequently associated with PTTM than other neoplasms. Interestingly, our 3 patients came from Latin American countries and were younger than most of the patients at gastric cancer diagnosis. Although the higher incidence of gastric cancer is described in Asian countries, such as Japan and Korea, a high incidence has also been seen in Central and South-America, as two-thirds of this malignancy is produced in developing countries. Median age of patients...
diagnosed with gastric cancer is around 50–70 years. However, several authors have described that patients with gastric cancer and cancer-related MAHA or PTTM are younger, regardless of their country of origin. There have also been described cases of PTTM associated with gastric cancer in children and adolescent patients, although the prevalence of gastric cancer in young generations is much lower. Patients with PTTM can present with different symptoms (weakness, weight loss, pain, fever, and respiratory symptoms) and can mimic different syndromes such as pulmonary hypertension, right heart failure, or organ dysfunction. In some cases, including the patients reported herein, MAHA and TMA are the predominant features of the clinical scenario, and differential diagnosis with TTP is then mandatory. Current diagnostic criteria of TTP include thrombocytopenia and MAHA without another apparent etiology. However, these clinical features are nonspecific and can be observed in other clinical conditions, including PTTM, inducing an inappropriate indication of plasma exchange therapy. It has been described that up to 7% of patients diagnosed with TTP (and almost 7% of the “idiopathic” cases) are really misdiagnosed MAHA secondary to a disseminated malignancy, whose main pathologic mechanism is microthrombi formation by tumor cells. When these microthrombi affect predominantly (but not only) pulmonary vessels and produce respiratory signs and symptoms, we call this entity PTTM. Thereby, although occult malignancy causing MAHA may be uncommon (George et al described 65 cases of systemic malignancies associated with MAHA and TMA in 30 years), it is important to consider it in the evaluation of patients with TTP. The cases in the current series reflect that PTTM and TMA due to disseminated malignancy present some atypical clinical and laboratory features that may help in the differential diagnosis. One of the main differences is the presence of pulmonary involvement. Typically TTP has been reported to spare the lungs. However, one should not consider that all TTP cases with lung involvement are due to PTTM. Actually, pulmonary affection in TTP is more common than generally appreciated: lung diseases can be the cause of a secondary TTP (pneumonia, chemotherapy-induced lung toxicity); and the lung can be involved in idiopathic TTP due to microthrombotic occlusion of pulmonary vessels or intraparenchymal hemorrhage associated with thrombopenia. There exist other features that are different in PTTM compared with TTP: a longer duration of symptoms, moderate thrombocytopenia, higher serum LDH levels, and abnormal coagulation tests. Regarding the levels of ADAMTS-13, it has been described that PTTM cases present a slight decrease instead of the severe deficient activity (<5%) typically seen in idiopathic TTP. Leukocytoclastic vasculitis in peripheral blood smear and increase of alkaline phosphatase could be indicative of bone marrow infiltration. The detection of lymphadenopathies in the CT images is also a common finding in PTTM. Finally, failure to response to plasma exchange is another characteristic of these patients. Differential diagnosis with PTTM should be considered not only in atypical TTP, but also in other conditions that may present with fulminant MAHA and could mimic a similar scenario, such as DIC or Trousseau syndrome. About one-third of patients with cancer-related MAHA show laboratory signs indicative of DIC, although malignancies can cause TMA without coagulation abnormalities. Trousseau syndrome consists of migratory thrombotic events that precede the diagnosis of an occult visceral malignancy or appear concomitantly with the tumor. It is consequence of multiple pathophysiologic mechanisms that contribute to the hypercoagulability associated with cancer, often occurring with mucin-positive carcinomas although it may be associated with other different types of cancer. It has been considered by some authors as a chronic or compensated DIC in the set of malignancy, where there is a slower rate of consumption of coagulation factors and platelets because liver and bone marrow are largely able to replenish them, so thrombosis manifestations are frequent rather than bleeding events. The typical clinical picture is venous and arterial microthrombi with secondary MAHA and that may also be associated with alteration of coagulation tests. However, in recent times, Trousseau syndrome is also used to describe any thrombotic complication associated with cancer, and usually affects large or medium veins in migratory thrombophlebitis, nonbacterial thrombotic endocarditis, arterial emboli or deep vein thrombosis associated or not with DIC differently from the clinical course of PTTM, where the principal location of the microvascular metastases is the lung. There are also physiopathologic differences, as Trousseau syndrome represents a spectrum of disorders, ranging with thrombosis induced primarily by the production of tissue factor by tumor cells, and platelet-rich microthrombotic process triggered by carcinoma mucins and other mechanisms that leads to thrombin generation and fibrin deposition, whereas the main problem in PTTM are the cancer cells embolism, mainly in the pulmonary microcirculation. Although pulmonary hypertension and cor pulmonale are classical signs documented in several case reports, they were not present in our patients. Actually, right ventricle enlargement or hypertrophy appears in less than 50% of patients with PTTM. Moreover, in the series of Von Herbay et al, 11/21 patients with PTTM died due to causes different that right cardiac failure. Essentially, patients with MAHA due to metastatic cancer have TMA not only in the lung, but also in other organs. Therefore, in our opinion, the term PTTM should be considered as part of a more generalized picture (“tumor thrombotic microangiopathy”) with TMA due to micrometastasis in the vessels of diverse organs leading to different possible clinical presentations. Although most of the cases are diagnosed in autopsies, if systematic malignancy is suspected, bone marrow biopsy, as well as biopsies of any suspected involved organs, would be appropriate. There are several reasons to make a prompt diagnosis of the systemic malignancy underlying PTTM. First, it provides an opportunity for treatment with appropriate chemotherapy. Although early recognition of cancer may not benefit these patients since they often have widely disseminated disease, some cases of improvement under treatment have been described. Second, the diagnosis allows establishing a prognosis: 90% of patients will die within 1 month, although it will depend on the underlying malignancy. Finally, timely diagnosis of systemic malignancy allows not starting or discontinuing plasma exchanges since this treatment is ineffective and can even be counterproductive. Indeed, some authors have hypothesized that plasma exchange might promote microthrombi formation, thereby worsening a chronic compensated state. In summary, disseminated malignancy, especially gastric cancer, and PTTM should be suspected in the presence of TMA presenting with atypical characteristics of TTP and/or alteration in coagulation tests, especially with lung involvement. These
patients usually need ICU admission and their outcome is rapidly fatal, so they are a medical challenge. Prompt diagnosis is important in order to establish a correct treatment and prognosis, avoiding ineffective therapies.

REFERENCES